<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cholesterol Therapies - Competitive Landscape Analysis</title>
    <link rel="stylesheet" href="styles.css">
      <script src="https://cdn.tailwindcss.com"></script>
</head>
<body class="light-mode">
    <header class="header mb-50">
        <div class="header-content">
            <div class="logo-container">
                <div class="logo-wrapper">
                    <img src="leaf.png" alt="Leaf Intelligence" class="logo-image">
                    <!-- Subtle glow effect -->
                    <div class="logo-glow"></div>
                </div>
                <div class="logo-text-container">
                    <div class="logo-text">Leaf Intelligence</div>
                    <div class="logo-subtitle">Cholesterol Therapies Analysis</div>
                </div>
            </div>
            <nav class="nav-tabs">
                <button class="nav-tab active" onclick="showTab('overview')">Overview</button>
                <button class="nav-tab" onclick="showTab('approved')">Competitors</button>
                <button class="nav-tab" onclick="showTab('comparison')">Comparison</button>
            </nav>

                <div class="theme-toggle" onclick="toggleTheme()">
        <div class="theme-toggle-slider">
            <svg class="sun-icon" viewBox="0 0 24 24" style="display: block;">
                <circle cx="12" cy="12" r="5"/>
                <line x1="12" y1="1" x2="12" y2="3"/>
                <line x1="12" y1="21" x2="12" y2="23"/>
                <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"/>
                <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"/>
                <line x1="1" y1="12" x2="3" y2="12"/>
                <line x1="21" y1="12" x2="23" y2="12"/>
                <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"/>
                <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"/>
            </svg>
            <svg class="moon-icon" viewBox="0 0 24 24" style="display: none;">
                <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"/>
            </svg>
        </div>
    </div>
        </div>
    </header>


    <div class="container">
        <!-- Overview Tab -->



<div class="min-h-screen bg-gradient-to-br from-gray-50 via-white to-gray-50 tab-content active" id="overview">
    <!-- Background decoration -->
<div class="fixed inset-0 opacity-[0.015] pointer-events-none">
  <div class="absolute inset-0"
       style="background-image: url('data:image/svg+xml,%3Csvg width=\'60\' height=\'60\' viewBox=\'0 0 60 60\' xmlns=\'http://www.w3.org/2000/svg\'%3E%3Cg fill=\'none\' fill-rule=\'evenodd\'%3E%3Cg fill=\'%236366f1\' fill-opacity=\'0.5\'%3E%3Cpath d=\'M0 0h20v20H0zm40 40h20v20H40z\'/%3E%3C/g%3E%3C/g%3E%3C/svg%3E');">
  </div>
</div>


    <div class="relative z-10  mx-auto px-4 py-8 max-w-7xl">
        <!-- Header -->
        <header class="glass rounded-xl p-8 mb-8 animate-fade-in hero-gradient">
            <div class="flex items-center justify-between">
                <div>
                    <h1 class="mb-2">Cholesterol Therapy Landscape 2025</h1>
                    <p class="text-sm text-gray-600 dark:text-gray-400">Comprehensive regulatory and market analysis of lipid-lowering therapies</p>
                </div>
                
                <!-- Theme Toggle -->
                <button onclick="toggleTheme()" class="relative w-16 h-8 rounded-full bg-gray-200 dark:bg-gray-700 transition-all duration-500 shadow-inner hover-lift">
                    <div class="absolute top-1 left-1 w-6 h-6 rounded-full bg-white dark:bg-gray-900 shadow-lg transform transition-transform duration-500" id="themeToggle">
                        <svg class="w-4 h-4 absolute top-1 left-1 text-yellow-500" id="sunIcon" viewBox="0 0 24 24" fill="currentColor">
                            <path d="M12 7a5 5 0 100 10 5 5 0 000-10z"/>
                        </svg>
                        <svg class="w-4 h-4 absolute top-1 left-1 text-indigo-400 opacity-0" id="moonIcon" viewBox="0 0 24 24" fill="currentColor">
                            <path d="M21 12.79A9 9 0 1111.21 3 7 7 0 0021 12.79z"/>
                        </svg>
                    </div>
                </button>
            </div>
        </header>

        <!-- Executive Summary -->
        <div class="glass rounded-xl p-8 mb-8 animate-fade-in stagger-1">
            <h2 class="flex items-center gap-2 mb-6">
                <span class="text-xl">ðŸŽ¯</span>
                Executive Summary
            </h2>
            <div class="grid grid-cols-1 lg:grid-cols-2 gap-8">
                <div>
                    <h3 class="mb-4">Current Market Reality</h3>
                    <ul class="executive-list">
                        <li class="animate-slide-in"><strong>Statins remain foundation</strong> - 90% of patients start here (generic, ~$10/month)</li>
                        <li class="animate-slide-in" style="animation-delay: 0.1s;"><strong>PCSK9 antibodies proven but underused</strong> - High cost ($5,800/year) limits access</li>
                        <li class="animate-slide-in" style="animation-delay: 0.2s;"><strong>Inclisiran's unique position</strong> - Only twice-yearly therapy, NHS deal shows potential</li>
                        <li class="animate-slide-in" style="animation-delay: 0.3s;"><strong>Step therapy barriers</strong> - Must fail 2-3 drugs before accessing advanced therapies</li>
                    </ul>
                </div>
                <div>
                    <h3 class="mb-4">What's Coming Next</h3>
                    <ul class="executive-list">
                        <li class="animate-slide-in" style="animation-delay: 0.4s;"><strong>Oral PCSK9 revolution (2025-26)</strong> - Daily pills matching injectable efficacy</li>
                        <li class="animate-slide-in" style="animation-delay: 0.5s;"><strong>Price competition intensifying</strong> - Biosimilars coming 2028, generics 2033+</li>
                        <li class="animate-slide-in" style="animation-delay: 0.6s;"><strong>Gene editing on horizon</strong> - One-time cure potential by 2030</li>
                        <li class="animate-slide-in" style="animation-delay: 0.7s;"><strong>Combination strategies emerging</strong> - Triple/quadruple therapy for ultra-low LDL</li>
                    </ul>
                </div>
            </div>
            <div class="insight-box mt-6">
                <p><span class="text-lg mr-2">ðŸ’¡</span><strong>Key Insight:</strong> The market is transitioning from "injectable vs oral" to "convenience vs compliance vs cost". Inclisiran's twice-yearly dosing offers guaranteed compliance, oral PCSK9i offers convenience, and biosimilars will offer cost savings. Success will depend on proving real-world outcomes and securing favorable payer agreements.</p>
            </div>
        </div>

        <!-- Key Terms and Treatment Pathway -->
        <div class="grid grid-cols-1 lg:grid-cols-2 gap-8 mb-8">
            <!-- Understanding Key Terms -->
            <div class="glass-card rounded-xl p-6 animate-fade-in stagger-2">
                <h3 class="flex items-center gap-2 mb-4">
                    <span class="text-lg">ðŸ“š</span>
                    Understanding Key Terms & Metrics
                </h3>
                <div class="grid grid-cols-2 gap-3">
                    <div class="metric-card">
                        <div class="metric-title">What is LDL-C?</div>
                        <div class="text-xs">
                            <strong>Low-Density Lipoprotein Cholesterol</strong><br>
                            "Bad cholesterol" that builds up in arteries<br>
                            Goal: &lt;70 mg/dL (high-risk)<br>
                            Goal: &lt;55 mg/dL (very high-risk)
                        </div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-title">What is MACE?</div>
                        <div class="text-xs">
                            <strong>Major Adverse Cardiovascular Events</strong><br>
                            Combined measure of heart attacks, strokes, CV death, and stents/bypass
                        </div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-title">What is PCSK9?</div>
                        <div class="text-xs">
                            <strong>Proprotein Convertase Subtilisin/Kexin 9</strong><br>
                            Protein that destroys LDL receptors. Blocking = more LDL removal
                        </div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-title">Dosing Abbreviations</div>
                        <div class="text-xs">
                            <strong>Q2W</strong> = Every 2 weeks<br>
                            <strong>Q4W</strong> = Monthly<br>
                            <strong>Q6M</strong> = Every 6 months
                        </div>
                    </div>
                </div>
            </div>

            <!-- Treatment Pathway -->
            <div class="glass-card rounded-xl p-6 animate-fade-in stagger-3">
                <h3 class="flex items-center gap-2 mb-4">
                    <span class="text-lg">ðŸ”„</span>
                    Treatment Decision Pathway
                </h3>
                <div class="flex items-center justify-between gap-2 mb-4">
                    <div class="pathway-step flex-1">
                        <div class="step-number">1</div>
                        <div class="text-xs font-medium text-gray-900 dark:text-white">Start Statin</div>
                        <div class="text-xs text-gray-500 dark:text-gray-400">30-50% LDLâ†“</div>
                    </div>
                    <span class="pathway-arrow">â†’</span>
                    <div class="pathway-step flex-1">
                        <div class="step-number">2</div>
                        <div class="text-xs font-medium text-gray-900 dark:text-white">Add Ezetimibe</div>
                        <div class="text-xs text-gray-500 dark:text-gray-400">+15-20% LDLâ†“</div>
                    </div>
                    <span class="pathway-arrow">â†’</span>
                    <div class="pathway-step flex-1">
                        <div class="step-number">3</div>
                        <div class="text-xs font-medium text-gray-900 dark:text-white">Consider Bempedoic</div>
                        <div class="text-xs text-gray-500 dark:text-gray-400">+18-25% LDLâ†“</div>
                    </div>
                    <span class="pathway-arrow">â†’</span>
                    <div class="pathway-step highlight flex-1">
                        <div class="step-number">4</div>
                        <div class="text-xs font-medium text-gray-900 dark:text-white">PCSK9 Therapy</div>
                        <div class="text-xs text-gray-500 dark:text-gray-400">+50-60% LDLâ†“</div>
                    </div>
                </div>
                <div class="info-box">
                    <strong>Note:</strong> Each step typically requires 6-12 weeks to assess response. Payers usually require documentation of inadequate response before approving next step.
                </div>
            </div>
        </div>

        <!-- EMA vs FDA Comparison -->
        <div class="glass rounded-xl p-6 mb-8 animate-fade-in stagger-4">
            <h3 class="mb-6">EMA vs FDA: Regulatory Comparison</h3>
            
            <!-- Inclisiran -->
            <div class="mb-6">
                <h3 class="text-sm font-medium mb-3 text-gray-700 dark:text-gray-300">Inclisiran (LeqvioÂ®) - Novartis</h3>
                <div class="grid grid-cols-1 md:grid-cols-2 gap-4">
                    <div class="agency-box ema">
                        <div class="font-medium mb-2 text-gray-900 dark:text-white">ðŸ‡ªðŸ‡º EMA Approval</div>
                        <div class="text-xs space-y-1">
                            <p><strong>Date:</strong> December 9, 2020</p>
                            <p><strong>Indication:</strong> Primary hypercholesterolaemia or mixed dyslipidaemia</p>
                            <p><strong>Administration:</strong> HCP dosing every 6 months</p>
                        </div>
                    </div>
                    <div class="agency-box fda">
                        <div class="font-medium mb-2 text-gray-900 dark:text-white">ðŸ‡ºðŸ‡¸ FDA Approval</div>
                        <div class="text-xs space-y-1">
                            <p><strong>Date:</strong> December 21, 2021 (12 months after EMA)</p>
                            <p><strong>Initial CRL:</strong> Manufacturing facility inspection issues (COVID)</p>
                            <p><strong>Label Expansion:</strong> July 2023 - broader primary hyperlipidaemia use</p>
                        </div>
                    </div>
                </div>
                <div class="info-box mt-3">
                    <strong>Divergence:</strong> EU approved one year earlier. US delay solely due to COVID-era facility inspection issues, not clinical concerns. Both await ORION-4 outcomes data (2026).
                </div>
            </div>

            <!-- Repatha -->
            <div class="mb-6">
                <h3 class="text-sm font-medium mb-3 text-gray-700 dark:text-gray-300">RepathaÂ® (evolocumab) - Amgen</h3>
                <div class="grid grid-cols-1 md:grid-cols-2 gap-4">
                    <div class="agency-box ema">
                        <div class="font-medium mb-2 text-gray-900 dark:text-white">ðŸ‡ªðŸ‡º EMA Approval</div>
                        <div class="text-xs space-y-1">
                            <p><strong>Date:</strong> 2015</p>
                            <p><strong>CV Risk Reduction:</strong> Added based on FOURIER trial</p>
                        </div>
                    </div>
                    <div class="agency-box fda">
                        <div class="font-medium mb-2 text-gray-900 dark:text-white">ðŸ‡ºðŸ‡¸ FDA Approval</div>
                        <div class="text-xs space-y-1">
                            <p><strong>Date:</strong> 2015</p>
                            <p><strong>CV Outcomes:</strong> 2017 - MI, stroke, revascularization reduction</p>
                        </div>
                    </div>
                </div>
                <div class="info-box mt-3">
                    <strong>Alignment:</strong> Both agencies approved simultaneously. CV outcomes added following FOURIER data.
                </div>
            </div>

            <!-- Pipeline Table -->
            <h3 class="text-sm font-medium mb-3 text-gray-700 dark:text-gray-300">Pipeline & Emerging Therapies</h3>
            <div class="overflow-x-auto">
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Drug/Company</th>
                            <th>Mechanism</th>
                            <th>Status</th>
                            <th>Key Events</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>LIB003</strong><br>LIB Therapeutics</td>
                            <td>Monthly PCSK9 adnectin</td>
                            <td>BLA accepted<br>PDUFA: Dec 12, 2025</td>
                            <td>Head-to-head vs inclisiran ongoing</td>
                        </tr>
                        <tr>
                            <td><strong>MK-0616</strong><br>Merck</td>
                            <td>Oral PCSK9 inhibitor</td>
                            <td>Phase 3 ongoing</td>
                            <td>Global program underway</td>
                        </tr>
                        <tr>
                            <td><strong>AZD0780</strong><br>AstraZeneca</td>
                            <td>Oral PCSK9 inhibitor</td>
                            <td>Phase 2b complete</td>
                            <td>PURSUIT trial met endpoints</td>
                        </tr>
                        <tr>
                            <td><strong>VERVE-101</strong><br>Eli Lilly</td>
                            <td>Gene editing</td>
                            <td>Clinical hold lifted</td>
                            <td>FDA hold resolved Oct 2023</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <!-- Compliance History -->
        <div class="glass rounded-xl p-6 mb-8 animate-fade-in">
            <h3 class="mb-2">Compliance History & Regulatory Analysis</h3>
            <p class="text-xs text-gray-600 dark:text-gray-400 mb-6">Minimal regulatory friction, mostly CMC-related issues</p>
            
            <div class="timeline">
                <div class="timeline-line"></div>
                
                <div class="timeline-item">
                    <div class="timeline-dot danger"></div>
                    <div class="timeline-content">
                        <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">DECEMBER 2020</div>
                        <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Inclisiran Complete Response Letter</div>
                        <div class="text-xs text-gray-600 dark:text-gray-400">
                            <strong>Issue:</strong> Third-party manufacturing facility inspection<br>
                            <strong>Context:</strong> COVID-19 restricted FDA access<br>
                            <strong>Important:</strong> No clinical/safety/efficacy concerns
                        </div>
                    </div>
                </div>

                <div class="timeline-item">
                    <div class="timeline-dot success"></div>
                    <div class="timeline-content">
                        <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">DECEMBER 21, 2021</div>
                        <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Inclisiran CRL Resolution</div>
                        <div class="text-xs text-gray-600 dark:text-gray-400">
                            <strong>Resolution:</strong> Facility inspection completed<br>
                            <strong>Outcome:</strong> Full FDA approval granted
                        </div>
                    </div>
                </div>

                <div class="timeline-item">
                    <div class="timeline-dot danger"></div>
                    <div class="timeline-content">
                        <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">NOVEMBER 2022</div>
                        <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">VERVE-101 Clinical Hold</div>
                        <div class="text-xs text-gray-600 dark:text-gray-400">
                            <strong>Product:</strong> PCSK9 gene editor<br>
                            <strong>Reason:</strong> First-in-human safety review<br>
                            <strong>Requirements:</strong> Additional safety data
                        </div>
                    </div>
                </div>

                <div class="timeline-item">
                    <div class="timeline-dot success"></div>
                    <div class="timeline-content">
                        <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">OCTOBER 2023</div>
                        <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">VERVE-101 Hold Lifted</div>
                        <div class="text-xs text-gray-600 dark:text-gray-400">
                            <strong>Resolution:</strong> FDA reviewed additional materials<br>
                            <strong>Outcome:</strong> US studies permitted to continue<br>
                            <strong>Note:</strong> Eli Lilly acquired assets July 2025
                        </div>
                    </div>
                </div>
            </div>

            <!-- Company Status Summary -->
            <h3 class="text-sm font-medium mt-8 mb-4 text-gray-700 dark:text-gray-300">Company Compliance Status</h3>
            <div class="grid grid-cols-1 md:grid-cols-2 gap-4">
                <div class="glass-card rounded-lg p-4 hover-lift">
                    <div class="flex justify-between items-center mb-2">
                        <strong class="text-gray-900 dark:text-white">Novartis (Inclisiran)</strong>
                        <span class="badge badge-warning">Resolved</span>
                    </div>
                    <p class="text-xs text-gray-600 dark:text-gray-400">CRL for CMC issues during COVID. No clinical concerns. Resolved in 12 months.</p>
                </div>
                <div class="glass-card rounded-lg p-4 hover-lift">
                    <div class="flex justify-between items-center mb-2">
                        <strong class="text-gray-900 dark:text-white">Amgen (Repatha)</strong>
                        <span class="badge badge-success">Clean</span>
                    </div>
                    <p class="text-xs text-gray-600 dark:text-gray-400">No CRLs or OPDP letters. 8+ years without compliance events.</p>
                </div>
                <div class="glass-card rounded-lg p-4 hover-lift">
                    <div class="flex justify-between items-center mb-2">
                        <strong class="text-gray-900 dark:text-white">Sanofi/Regeneron (Praluent)</strong>
                        <span class="badge badge-success">Clean</span>
                    </div>
                    <p class="text-xs text-gray-600 dark:text-gray-400">Clean approval pathway. No OPDP enforcement actions.</p>
                </div>
                <div class="glass-card rounded-lg p-4 hover-lift">
                    <div class="flex justify-between items-center mb-2">
                        <strong class="text-gray-900 dark:text-white">Verve/Eli Lilly (Gene Editing)</strong>
                        <span class="badge badge-warning">Hold Lifted</span>
                    </div>
                    <p class="text-xs text-gray-600 dark:text-gray-400">Clinical hold for gene editing safety. Resolved with additional data.</p>
                </div>
            </div>
        </div>

        <!-- Market Evolution Timeline -->
        <div class="glass rounded-xl p-6 mb-8 animate-fade-in">
            <h3 class="mb-6">5-10 Year Market Evolution</h3>
            <div class="timeline">
                <div class="timeline-line"></div>
                
                <div class="timeline-item">
                    <div class="timeline-dot success"></div>
                    <div class="timeline-content">
                        <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">2025-2027</div>
                        <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Oral Revolution</div>
                        <div class="text-xs text-gray-600 dark:text-gray-400">
                            â€¢ MK-0616, AZD0780 enter market<br>
                            â€¢ LIB003 approved as monthly option<br>
                            â€¢ Inclisiran ORION-4 validates CV benefit<br>
                            â€¢ Price competition intensifies
                        </div>
                    </div>
                </div>

                <div class="timeline-item">
                    <div class="timeline-dot warning"></div>
                    <div class="timeline-content">
                        <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">2028-2030</div>
                        <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Biosimilar Era</div>
                        <div class="text-xs text-gray-600 dark:text-gray-400">
                            â€¢ PCSK9 mAb biosimilars arrive<br>
                            â€¢ Oral PCSK9i dominate new prescriptions<br>
                            â€¢ Gene editing potentially approved for FH<br>
                            â€¢ Combination pills emerge
                        </div>
                    </div>
                </div>

                <div class="timeline-item">
                    <div class="timeline-dot success"></div>
                    <div class="timeline-content">
                        <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">2030-2035</div>
                        <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Precision Medicine</div>
                        <div class="text-xs text-gray-600 dark:text-gray-400">
                            â€¢ Personalized therapy selection<br>
                            â€¢ Gene editing for broader populations<br>
                            â€¢ Ultra-low cost generics<br>
                            â€¢ Primary prevention expansion
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <!-- Technical Specifications -->
        <div class="glass rounded-xl p-6 animate-fade-in overflow-x-auto">
            <h3 class="mb-4">Technical & Clinical Specifications</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Drug</th>
                        <th>Mechanism</th>
                        <th>LDL-C Reduction</th>
                        <th>Dosing</th>
                        <th>Administration</th>
                        <th>CV Outcomes</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Inclisiran</strong></td>
                        <td>siRNA</td>
                        <td>50-52%</td>
                        <td>Q6M</td>
                        <td>SC by HCP</td>
                        <td>Pending (2026)</td>
                    </tr>
                    <tr>
                        <td><strong>Repatha</strong></td>
                        <td>PCSK9 mAb</td>
                        <td>60%</td>
                        <td>Q2W/Monthly</td>
                        <td>SC self-injection</td>
                        <td>15% MACE â†“</td>
                    </tr>
                    <tr>
                        <td><strong>Praluent</strong></td>
                        <td>PCSK9 mAb</td>
                        <td>45-60%</td>
                        <td>Q2W/Q4W</td>
                        <td>SC self-injection</td>
                        <td>15% MACE â†“</td>
                    </tr>
                    <tr>
                        <td><strong>Bempedoic Acid</strong></td>
                        <td>ACL inhibitor</td>
                        <td>18-25%</td>
                        <td>Daily</td>
                        <td>Oral</td>
                        <td>13% MACE â†“</td>
                    </tr>
                    <tr>
                        <td><strong>MK-0616</strong> (pipeline)</td>
                        <td>Oral PCSK9i</td>
                        <td>60%</td>
                        <td>Daily</td>
                        <td>Oral</td>
                        <td>Phase 3</td>
                    </tr>
                </tbody>
            </table>
        </div>
    </div>

   


</div>
































    <div id='approved' class="tab-content ">
        <div class="table-header">
            <div class="header-top">
                <h2 class="table-title">
                    <div class="title-icon">
                        <svg viewBox="0 0 24 24" fill="none">
                            <path d="M9 11H3V21H9V11Z" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"/>
                            <path d="M15 3H9V21H15V3Z" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"/>
                            <path d="M21 7H15V21H21V7Z" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"/>
                        </svg>
                    </div>
                    Competitive Landscape Analysis
                </h2>
                <div class="theme-toggle" onclick="toggleTheme()">
                    <div class="theme-toggle-slider">
                        <svg class="sun-icon" viewBox="0 0 24 24" style="display: block;">
                            <circle cx="12" cy="12" r="5"/>
                            <line x1="12" y1="1" x2="12" y2="3"/>
                            <line x1="12" y1="21" x2="12" y2="23"/>
                            <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"/>
                            <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"/>
                            <line x1="1" y1="12" x2="3" y2="12"/>
                            <line x1="21" y1="12" x2="23" y2="12"/>
                            <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"/>
                            <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"/>
                        </svg>
                        <svg class="moon-icon" viewBox="0 0 24 24" style="display: none;">
                            <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"/>
                        </svg>
                    </div>
                </div>
            </div>
            <div class="filter-controls">
                <button class="filter-btn active" onclick="filterTable('all', event)">All Therapies</button>
                <button class="filter-btn" onclick="filterTable('approved', event)">Approved</button>
                <button class="filter-btn" onclick="filterTable('pipeline', event)">Pipeline</button>
                <button class="filter-btn" onclick="filterTable('pcsk9', event)">PCSK9 Inhibitors</button>
                <button class="filter-btn" onclick="filterTable('other', event)">Other Mechanisms</button>
            </div>
        </div>

        <div class="table-wrapper">
            <table class="competitors-table">
                <thead>
                    <tr>
                        <th>Drug / Company</th>
                        <th>Status</th>
                        <th>Dosing</th>
                        <th>Efficacy</th>
                        <th>Recent Events</th>
                        <th>Actions</th>
                    </tr>
                </thead>
                <tbody>
                    <!-- Approved Therapies -->
                    <tr class="approved pcsk9">
                        <td>
                            <div class="drug-info">
                                <div class="drug-name">RepathaÂ® (evolocumab)</div>
                                <div class="drug-company">Amgen</div>
                                <div class="drug-mechanism">PCSK9 Monoclonal Antibody</div>
                            </div>
                        </td>
                        <td>
                            <div class="status-container">
                                <span class="status-badge status-approved">
                                    âœ“ Approved
                                </span>
                                <div class="approval-info">FDA/EMA 2015</div>
                            </div>
                        </td>
                        <td>
                            <div class="dosing-info">
                                <div class="dosing-primary">140 mg Q2W or 420 mg monthly</div>
                                <div class="dosing-secondary">SC â€¢ 12-26 injections/year</div>
                            </div>
                        </td>
                        <td>
                            <div class="efficacy-container">
                                <div class="efficacy-bar">
                                    <div class="efficacy-fill" style="width: 60%;">~60% LDLâ†“</div>
                                </div>
                                <div class="efficacy-label">15% MACE reduction</div>
                            </div>
                        </td>
                        <td>
                            <div class="recent-events">
                                <div class="event-item">
                                    <span class="event-icon">$</span>
                                    <span>Price cut 60% post-outcomes</span>
                                </div>
                                <div class="event-item">
                                    <span class="event-icon">âœ“</span>
                                    <span>8+ years safety record</span>
                                </div>
                            </div>
                        </td>
                        <td>
                            <div class="action-buttons">
                                <a href="repatha.html" class="action-btn btn-primary">
                                    View Details
                                </a>
                                <a href="https://leaf.intelligence/search?q=evolocumab" target="_blank" class="action-btn btn-secondary">
                                    Leaf Intel
                                </a>
                            </div>
                        </td>
                    </tr>

                    <tr class="approved pcsk9">
                        <td>
                            <div class="drug-info">
                                <div class="drug-name">PraluentÂ® (alirocumab)</div>
                                <div class="drug-company">Sanofi/Regeneron</div>
                                <div class="drug-mechanism">PCSK9 Monoclonal Antibody</div>
                            </div>
                        </td>
                        <td>
                            <div class="status-container">
                                <span class="status-badge status-approved">
                                    âœ“ Approved
                                </span>
                                <div class="approval-info">FDA/EMA 2015</div>
                            </div>
                        </td>
                        <td>
                            <div class="dosing-info">
                                <div class="dosing-primary">75-150 mg Q2W or 300 mg monthly</div>
                                <div class="dosing-secondary">SC â€¢ 12-26 injections/year</div>
                            </div>
                        </td>
                        <td>
                            <div class="efficacy-container">
                                <div class="efficacy-bar">
                                    <div class="efficacy-fill" style="width: 55%;">50-60% LDLâ†“</div>
                                </div>
                                <div class="efficacy-label">15% MACE, 15% mortalityâ†“</div>
                            </div>
                        </td>
                        <td>
                            <div class="recent-events">
                                <div class="event-item">
                                    <span class="event-icon">â˜…</span>
                                    <span>Only PCSK9i w/ mortality</span>
                                </div>
                                <div class="event-item">
                                    <span class="event-icon">âœ“</span>
                                    <span>Patent resolved</span>
                                </div>
                            </div>
                        </td>
                        <td>
                            <div class="action-buttons">
                                <a href="praluent.html" class="action-btn btn-primary">
                                    View Details
                                </a>
                                <a href="https://leaf.intelligence/search?q=alirocumab" target="_blank" class="action-btn btn-secondary">
                                    Leaf Intel
                                </a>
                            </div>
                        </td>
                    </tr>

                    <tr class="approved pcsk9">
                        <td>
                            <div class="drug-info">
                                <div class="drug-name">Ebronucimab (AK102)</div>
                                <div class="drug-company">Akeso Inc.</div>
                                <div class="drug-mechanism">PCSK9 Monoclonal Antibody</div>
                            </div>
                        </td>
                        <td>
                            <div class="status-container">
                                <span class="status-badge status-approved">
                                    âœ“ Approved
                                </span>
                                <div class="approval-info">China NMPA 2024</div>
                            </div>
                        </td>
                        <td>
                            <div class="dosing-info">
                                <div class="dosing-primary">Q2W, Q4W, or Q6W</div>
                                <div class="dosing-secondary">SC â€¢ 8-26 injections/year</div>
                            </div>
                        </td>
                        <td>
                            <div class="efficacy-container">
                                <div class="efficacy-bar">
                                    <div class="efficacy-fill" style="width: 65%;">Up to 65% LDLâ†“</div>
                                </div>
                                <div class="efficacy-label">CV outcomes pending</div>
                            </div>
                        </td>
                        <td>
                            <div class="recent-events">
                                <div class="event-item">
                                    <span class="event-icon">CN</span>
                                    <span>China-only approval</span>
                                </div>
                                <div class="event-item">
                                    <span class="event-icon">6W</span>
                                    <span>Q6W dosing advantage</span>
                                </div>
                            </div>
                        </td>
                        <td>
                            <div class="action-buttons">
                                <a href="ebronucimab.html" class="action-btn btn-primary">
                                    View Details
                                </a>
                                <a href="https://leaf.intelligence/search?q=ebronucimab" target="_blank" class="action-btn btn-secondary">
                                    Leaf Intel
                                </a>
                            </div>
                        </td>
                    </tr>

                    <tr class="approved other">
                        <td>
                            <div class="drug-info">
                                <div class="drug-name">NexletolÂ® (bempedoic acid)</div>
                                <div class="drug-company">Esperion Therapeutics</div>
                                <div class="drug-mechanism">ACL Inhibitor</div>
                            </div>
                        </td>
                        <td>
                            <div class="status-container">
                                <span class="status-badge status-approved">
                                    âœ“ Approved
                                </span>
                                <div class="approval-info">FDA/EMA 2020</div>
                            </div>
                        </td>
                        <td>
                            <div class="dosing-info">
                                <div class="dosing-primary">180 mg oral once daily</div>
                                <div class="dosing-secondary">~$400/month (US)</div>
                            </div>
                        </td>
                        <td>
                            <div class="efficacy-container">
                                <div class="efficacy-bar">
                                    <div class="efficacy-fill" style="width: 22%;">18-25% LDLâ†“</div>
                                </div>
                                <div class="efficacy-label">13% MACE, 23% MIâ†“</div>
                            </div>
                        </td>
                        <td>
                            <div class="recent-events">
                                <div class="event-item">
                                    <span class="event-icon">Rx</span>
                                    <span>Statin-intolerant pts</span>
                                </div>
                                <div class="event-item">
                                    <span class="event-icon">âœ“</span>
                                    <span>CLEAR positive</span>
                                </div>
                            </div>
                        </td>
                        <td>
                            <div class="action-buttons">
                                <a href="nexletol.html" class="action-btn btn-primary">
                                    View Details
                                </a>
                                <a href="https://leaf.intelligence/search?q=bempedoic+acid" target="_blank" class="action-btn btn-secondary">
                                    Leaf Intel
                                </a>
                            </div>
                        </td>
                    </tr>

                    <tr class="approved other">
                        <td>
                            <div class="drug-info">
                                <div class="drug-name">Ezetimibe (ZetiaÂ®)</div>
                                <div class="drug-company">Generic (Originally Merck)</div>
                                <div class="drug-mechanism">Cholesterol Absorption Inhibitor</div>
                            </div>
                        </td>
                        <td>
                            <div class="status-container">
                                <span class="status-badge status-approved">
                                    âœ“ Approved
                                </span>
                                <div class="approval-info">FDA 2002 (Generic)</div>
                            </div>
                        </td>
                        <td>
                            <div class="dosing-info">
                                <div class="dosing-primary">10 mg oral once daily</div>
                                <div class="dosing-secondary">~$10-20/month (generic)</div>
                            </div>
                        </td>
                        <td>
                            <div class="efficacy-container">
                                <div class="efficacy-bar">
                                    <div class="efficacy-fill" style="width: 20%;">15-25% LDLâ†“</div>
                                </div>
                                <div class="efficacy-label">6-7% MACEâ†“</div>
                            </div>
                        </td>
                        <td>
                            <div class="recent-events">
                                <div class="event-item">
                                    <span class="event-icon">2</span>
                                    <span>Standard 2nd-line</span>
                                </div>
                                <div class="event-item">
                                    <span class="event-icon">âœ“</span>
                                    <span>Well-tolerated</span>
                                </div>
                            </div>
                        </td>
                        <td>
                            <div class="action-buttons">
                                <a href="ezetimibe.html" class="action-btn btn-primary">
                                    View Details
                                </a>
                                <a href="https://leaf.intelligence/search?q=ezetimibe" target="_blank" class="action-btn btn-secondary">
                                    Leaf Intel
                                </a>
                            </div>
                        </td>
                    </tr>

                    <!-- Pipeline Therapies -->
                    <tr class="pipeline pcsk9">
                        <td>
                            <div class="drug-info">
                                <div class="drug-name">MK-0616 (enplicitide)</div>
                                <div class="drug-company">Merck</div>
                                <div class="drug-mechanism">Oral PCSK9 Inhibitor (Macrocyclic Peptide)</div>
                            </div>
                        </td>
                        <td>
                            <div class="status-container">
                                <span class="status-badge status-pipeline">
                                    â§— Pipeline
                                </span>
                                <div class="approval-info">Phase 3 (17,000 pts)</div>
                            </div>
                        </td>
                        <td>
                            <div class="dosing-info">
                                <div class="dosing-primary">6-30 mg oral once daily</div>
                                <div class="dosing-secondary">First-in-class oral PCSK9i</div>
                            </div>
                        </td>
                        <td>
                            <div class="efficacy-container">
                                <div class="efficacy-bar">
                                    <div class="efficacy-fill" style="width: 60%;">~60% LDLâ†“</div>
                                </div>
                                <div class="efficacy-label">CORALreef outcomes 2029</div>
                            </div>
                        </td>
                        <td>
                            <div class="recent-events">
                                <div class="event-item">
                                    <span class="event-icon">P3</span>
                                    <span>Phase 3 Aug 2023</span>
                                </div>
                                <div class="event-item">
                                    <span class="event-icon">26</span>
                                    <span>Approval exp. 2025-26</span>
                                </div>
                            </div>
                        </td>
                        <td>
                            <div class="action-buttons">
                                <a href="mk0616.html" class="action-btn btn-primary">
                                    View Details
                                </a>
                                <a href="https://leaf.intelligence/search?q=MK-0616" target="_blank" class="action-btn btn-secondary">
                                    Leaf Intel
                                </a>
                            </div>
                        </td>
                    </tr>

                    <tr class="pipeline pcsk9">
                        <td>
                            <div class="drug-info">
                                <div class="drug-name">AZD0780</div>
                                <div class="drug-company">AstraZeneca</div>
                                <div class="drug-mechanism">Oral PCSK9 Inhibitor (Small Molecule)</div>
                            </div>
                        </td>
                        <td>
                            <div class="status-container">
                                <span class="status-badge status-pipeline">
                                    â§— Pipeline
                                </span>
                                <div class="approval-info">Phase 2 Complete</div>
                            </div>
                        </td>
                        <td>
                            <div class="dosing-info">
                                <div class="dosing-primary">30 mg oral once daily</div>
                                <div class="dosing-secondary">Can be taken with/without food</div>
                            </div>
                        </td>
                        <td>
                            <div class="efficacy-container">
                                <div class="efficacy-bar">
                                    <div class="efficacy-fill" style="width: 51%;">50.7% LDLâ†“</div>
                                </div>
                                <div class="efficacy-label">Alzheimer's biomarkerâ†“</div>
                            </div>
                        </td>
                        <td>
                            <div class="recent-events">
                                <div class="event-item">
                                    <span class="event-icon">UK</span>
                                    <span>Innovation Passport</span>
                                </div>
                                <div class="event-item">
                                    <span class="event-icon">P3</span>
                                    <span>Phase 3 in 2025</span>
                                </div>
                            </div>
                        </td>
                        <td>
                            <div class="action-buttons">
                                <a href="azd0780.html" class="action-btn btn-primary">
                                    View Details
                                </a>
                                <a href="https://leaf.intelligence/search?q=AZD0780" target="_blank" class="action-btn btn-secondary">
                                    Leaf Intel
                                </a>
                            </div>
                        </td>
                    </tr>

                    <tr class="pipeline pcsk9">
                        <td>
                            <div class="drug-info">
                                <div class="drug-name">LIB003 (lerodalcibep)</div>
                                <div class="drug-company">LIB Therapeutics</div>
                                <div class="drug-mechanism">Monthly PCSK9 Inhibitor (Adnectin)</div>
                            </div>
                        </td>
                        <td>
                            <div class="status-container">
                                <span class="status-badge status-pipeline">
                                    â§— Pipeline
                                </span>
                                <div class="approval-info">Filing 2025</div>
                            </div>
                        </td>
                        <td>
                            <div class="dosing-info">
                                <div class="dosing-primary">300 mg SC monthly</div>
                                <div class="dosing-secondary">Small volume: 1.2 mL</div>
                            </div>
                        </td>
                        <td>
                            <div class="efficacy-container">
                                <div class="efficacy-bar">
                                    <div class="efficacy-fill" style="width: 56%;">56% LDLâ†“</div>
                                </div>
                                <div class="efficacy-label">FDA Fast Track</div>
                            </div>
                        </td>
                        <td>
                            <div class="recent-events">
                                <div class="event-item">
                                    <span class="event-icon">52</span>
                                    <span>52-week positive</span>
                                </div>
                                <div class="event-item">
                                    <span class="event-icon">âœ“</span>
                                    <span>No immunogenicity</span>
                                </div>
                            </div>
                        </td>
                        <td>
                            <div class="action-buttons">
                                <a href="lib003.html" class="action-btn btn-primary">
                                    View Details
                                </a>
                                <a href="https://leaf.intelligence/search?q=lerodalcibep" target="_blank" class="action-btn btn-secondary">
                                    Leaf Intel
                                </a>
                            </div>
                        </td>
                    </tr>

                    <tr class="pipeline other">
                        <td>
                            <div class="drug-info">
                                <div class="drug-name">Obicetrapib</div>
                                <div class="drug-company">NewAmsterdam Pharma</div>
                                <div class="drug-mechanism">CETP Inhibitor</div>
                            </div>
                        </td>
                        <td>
                            <div class="status-container">
                                <span class="status-badge status-pipeline">
                                    â§— Pipeline
                                </span>
                                <div class="approval-info">EMA Filed Aug 2025</div>
                            </div>
                        </td>
                        <td>
                            <div class="dosing-info">
                                <div class="dosing-primary">10 mg oral once daily</div>
                                <div class="dosing-secondary">Fixed-dose combo w/ ezetimibe</div>
                            </div>
                        </td>
                        <td>
                            <div class="efficacy-container">
                                <div class="efficacy-bar">
                                    <div class="efficacy-fill" style="width: 45%;">35-45% LDLâ†“</div>
                                </div>
                                <div class="efficacy-label">HDL >100%â†‘</div>
                            </div>
                        </td>
                        <td>
                            <div class="recent-events">
                                <div class="event-item">
                                    <span class="event-icon">EU</span>
                                    <span>EMA filing submitted</span>
                                </div>
                                <div class="event-item">
                                    <span class="event-icon">CV</span>
                                    <span>PREVAIL ongoing</span>
                                </div>
                            </div>
                        </td>
                        <td>
                            <div class="action-buttons">
                                <a href="obicetrapib.html" class="action-btn btn-primary">
                                    View Details
                                </a>
                                <a href="https://leaf.intelligence/search?q=obicetrapib" target="_blank" class="action-btn btn-secondary">
                                    Leaf Intel
                                </a>
                            </div>
                        </td>
                    </tr>

                    <tr class="pipeline other">
                        <td>
                            <div class="drug-info">
                                <div class="drug-name">VERVE-101</div>
                                <div class="drug-company">Verve Therapeutics (Acquired by Eli Lilly)</div>
                                <div class="drug-mechanism">PCSK9 Gene Editing (Base Editor)</div>
                            </div>
                        </td>
                        <td>
                            <div class="status-container">
                                <span class="status-badge status-pipeline">
                                    â§— Pipeline
                                </span>
                                <div class="approval-info">Phase 1</div>
                            </div>
                        </td>
                        <td>
                            <div class="dosing-info">
                                <div class="dosing-primary">One-time IV infusion</div>
                                <div class="dosing-secondary">Permanent PCSK9 knockout</div>
                            </div>
                        </td>
                        <td>
                            <div class="efficacy-container">
                                <div class="efficacy-bar">
                                    <div class="efficacy-fill" style="width: 60%;">~60% LDLâ†“</div>
                                </div>
                                <div class="efficacy-label">Permanent effect</div>
                            </div>
                        </td>
                        <td>
                            <div class="recent-events">
                                <div class="event-item">
                                    <span class="event-icon">$B</span>
                                    <span>$1.3B acquisition</span>
                                </div>
                                <div class="event-item">
                                    <span class="event-icon">âœ“</span>
                                    <span>FDA hold lifted</span>
                                </div>
                            </div>
                        </td>
                        <td>
                            <div class="action-buttons">
                                <a href="verve101.html" class="action-btn btn-primary">
                                    View Details
                                </a>
                                <a href="https://leaf.intelligence/search?q=VERVE-101" target="_blank" class="action-btn btn-secondary">
                                    Leaf Intel
                                </a>
                            </div>
                        </td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">11</div>
                <div class="stat-label">Total Therapies</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Approved</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Pipeline</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">8</div>
                <div class="stat-label">PCSK9 Inhibitors</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Oral Options</div>
            </div>
        </div>
    </div>
        
<div id='comparison' class="tab-content ">
        <!-- Comprehensive Feature Comparison -->
        <div class="comparison-section">
            <div class="section-header">
                <h3 class="section-title">
                    <div class="title-icon">
                        <svg viewBox="0 0 24 24" fill="none">
                            <path d="M9 11H3V21H9V11Z" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"/>
                            <path d="M15 3H9V21H15V3Z" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"/>
                            <path d="M21 7H15V21H21V7Z" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"/>
                        </svg>
                    </div>
                    Comprehensive Feature Comparison
                </h3>
            </div>
            
            <div class="info-box">
                <p><strong>Guide:</strong> This table compares all therapies across key dimensions. Inclisiran (reference) is highlighted. 
                Click any row for detailed information. Green badges indicate proven CV outcomes.</p>
            </div>
            
            <div class="table-wrapper">
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Therapy</th>
                            <th>Mechanism</th>
                            <th>Dosing</th>
                            <th>LDL Reduction</th>
                            <th>CV Outcomes</th>
                            <th>Annual Cost</th>
                            <th>Status</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr class="highlight-row">
                            <td><strong>Inclisiran</strong></td>
                            <td>PCSK9 siRNA</td>
                            <td><strong>2x/year SC</strong></td>
                            <td>50-52%</td>
                            <td><span class="badge badge-warning">Pending (2026)</span></td>
                            <td>~$6,500</td>
                            <td>Approved</td>
                        </tr>
                        <tr class="clickable-row" onclick="window.location.href='repatha-details.html'">
                            <td>Repatha</td>
                            <td>PCSK9 mAb</td>
                            <td>Q2W or monthly SC</td>
                            <td>60%</td>
                            <td><span class="badge badge-success">âœ“ 15% MACEâ†“</span></td>
                            <td>~$5,800</td>
                            <td>Approved</td>
                        </tr>
                        <tr class="clickable-row" onclick="window.location.href='praluent-details.html'">
                            <td>Praluent</td>
                            <td>PCSK9 mAb</td>
                            <td>Q2W or monthly SC</td>
                            <td>50-60%</td>
                            <td><span class="badge badge-success">âœ“ 15% MACE, 15% mortalityâ†“</span></td>
                            <td>~$5,850</td>
                            <td>Approved</td>
                        </tr>
                        <tr>
                            <td>Ebronucimab</td>
                            <td>PCSK9 mAb</td>
                            <td>Q6W SC option</td>
                            <td>65%</td>
                            <td>No data</td>
                            <td>TBD (China)</td>
                            <td>China only</td>
                        </tr>
                        <tr>
                            <td>MK-0616</td>
                            <td>Oral PCSK9i</td>
                            <td><strong>Daily oral</strong></td>
                            <td>60%</td>
                            <td><span class="badge badge-warning">Trial 2029</span></td>
                            <td>TBD</td>
                            <td>Phase 3</td>
                        </tr>
                        <tr>
                            <td>AZD0780</td>
                            <td>Oral PCSK9i</td>
                            <td><strong>Daily oral</strong></td>
                            <td>50%</td>
                            <td>Planned</td>
                            <td>TBD</td>
                            <td>Phase 2/3</td>
                        </tr>
                        <tr>
                            <td>LIB003</td>
                            <td>PCSK9 binder</td>
                            <td>Monthly SC</td>
                            <td>56%</td>
                            <td>No data yet</td>
                            <td>TBD</td>
                            <td>Filing 2025</td>
                        </tr>
                        <tr>
                            <td>Bempedoic Acid</td>
                            <td>ACL inhibitor</td>
                            <td>Daily oral</td>
                            <td>18-25%</td>
                            <td><span class="badge badge-success">âœ“ 13% MACE, 23% MIâ†“</span></td>
                            <td>~$4,800</td>
                            <td>Approved</td>
                        </tr>
                        <tr>
                            <td>Ezetimibe</td>
                            <td>NPC1L1 inhibitor</td>
                            <td>Daily oral</td>
                            <td>15-25%</td>
                            <td><span class="badge badge-success">âœ“ 6-7% MACEâ†“</span></td>
                            <td>Generic (~$120)</td>
                            <td>Approved</td>
                        </tr>
                        <tr>
                            <td>Statins</td>
                            <td>HMG-CoA reductase</td>
                            <td>Daily oral</td>
                            <td>30-50%</td>
                            <td><span class="badge badge-success">âœ“ 25-35% CVâ†“</span></td>
                            <td>Generic (~$60)</td>
                            <td>Standard</td>
                        </tr>
                        <tr>
                            <td>Obicetrapib</td>
                            <td>CETP inhibitor</td>
                            <td>Daily oral</td>
                            <td>35-45% (+HDLâ†‘)</td>
                            <td><span class="badge badge-warning">PREVAIL ongoing</span></td>
                            <td>TBD</td>
                            <td>EU Filed</td>
                        </tr>
                        <tr>
                            <td>Evinacumab</td>
                            <td>ANGPTL3 mAb</td>
                            <td>Monthly IV</td>
                            <td>47% (HoFH)</td>
                            <td>N/A (orphan)</td>
                            <td>~$450,000</td>
                            <td>HoFH only</td>
                        </tr>
                        <tr>
                            <td>VERVE-101</td>
                            <td>Gene editing</td>
                            <td><strong>One-time</strong></td>
                            <td>60% (permanent)</td>
                            <td>N/A</td>
                            <td>>$100,000?</td>
                            <td>Phase 1</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <!-- Dosing Frequency Analysis -->
        <div class="comparison-section">
            <div class="section-header">
                <h3 class="section-title">
                    <div class="title-icon">
                        <svg viewBox="0 0 24 24" fill="none">
                            <path d="M12 2L2 7V12C2 16.55 4.84 20.74 9 22C13.16 20.74 22 16.55 22 12V7L12 2Z" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"/>
                        </svg>
                    </div>
                    Dosing Frequency Analysis
                </h3>
            </div>
            
            <div class="stats-grid">
                <div class="stat-card">
                    <div class="stat-value">1</div>
                    <div class="stat-label">One-Time (Gene editing)</div>
                </div>
                <div class="stat-card">
                    <div class="stat-value">2</div>
                    <div class="stat-label">Per Year (Inclisiran)</div>
                </div>
                <div class="stat-card">
                    <div class="stat-value">12</div>
                    <div class="stat-label">Monthly (LIB003, Evinacumab)</div>
                </div>
                <div class="stat-card">
                    <div class="stat-value">365</div>
                    <div class="stat-label">Daily (All oral agents)</div>
                </div>
            </div>
        </div>

        <!-- Clinical Trials Tracker -->
        <div class="comparison-section">
            <div class="section-header">
                <h3 class="section-title">
                    <div class="title-icon">
                        <svg viewBox="0 0 24 24" fill="none">
                            <path d="M9 5H7C5.89543 5 5 5.89543 5 7V19C5 20.1046 5.89543 21 7 21H17C18.1046 21 19 20.1046 19 19V7C19 5.89543 18.1046 5 17 5H15" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"/>
                            <path d="M9 5C9 3.89543 9.89543 3 11 3H13C14.1046 3 15 3.89543 15 5V7H9V5Z" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"/>
                        </svg>
                    </div>
                    Clinical Trials Tracker
                </h3>
            </div>
            
            <div class="filter-controls">
                <button class="filter-btn active" onclick="filterTrials('all', event)">All Trials</button>
                <button class="filter-btn" onclick="filterTrials('ongoing', event)">Ongoing</button>
                <button class="filter-btn" onclick="filterTrials('complete', event)">Complete</button>
                <button class="filter-btn" onclick="filterTrials('phase1', event)">Phase 1</button>
            </div>
            
            <div class="table-wrapper">
                <table class="data-table" id="trials-table">
                    <thead>
                        <tr>
                            <th>Trial Name</th>
                            <th>Drug</th>
                            <th>Status</th>
                            <th>N</th>
                            <th>Primary Endpoint</th>
                            <th>Timeline</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr data-status="ongoing">
                            <td><strong>ORION-4</strong></td>
                            <td>Inclisiran</td>
                            <td><span class="badge badge-warning">Ongoing</span></td>
                            <td>15,000</td>
                            <td>CV outcomes</td>
                            <td>Results ~2026</td>
                        </tr>
                        <tr data-status="complete">
                            <td>FOURIER</td>
                            <td>Repatha</td>
                            <td><span class="badge badge-success">Complete</span></td>
                            <td>27,564</td>
                            <td>MACE</td>
                            <td>15% MACE reduction</td>
                        </tr>
                        <tr data-status="complete">
                            <td>ODYSSEY Outcomes</td>
                            <td>Praluent</td>
                            <td><span class="badge badge-success">Complete</span></td>
                            <td>18,924</td>
                            <td>MACE</td>
                            <td>15% MACE, 15% mortalityâ†“</td>
                        </tr>
                        <tr data-status="ongoing">
                            <td>CORALreef Outcomes</td>
                            <td>MK-0616</td>
                            <td><span class="badge badge-warning">Enrolling</span></td>
                            <td>14,000</td>
                            <td>CV outcomes</td>
                            <td>Results ~2029</td>
                        </tr>
                        <tr data-status="complete">
                            <td>CLEAR Outcomes</td>
                            <td>Bempedoic Acid</td>
                            <td><span class="badge badge-success">Complete</span></td>
                            <td>13,970</td>
                            <td>4-point MACE</td>
                            <td>13% MACE, 23% MIâ†“</td>
                        </tr>
                        <tr data-status="ongoing">
                            <td>PREVAIL</td>
                            <td>Obicetrapib</td>
                            <td><span class="badge badge-warning">Ongoing</span></td>
                            <td>TBD</td>
                            <td>CV outcomes</td>
                            <td>Results ~2026</td>
                        </tr>
                        <tr data-status="phase1">
                            <td>HEART-1</td>
                            <td>VERVE-101</td>
                            <td><span class="badge badge-info">Phase 1</span></td>
                            <td>~40</td>
                            <td>Safety/LDL</td>
                            <td>Ongoing</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <!-- Market Access & Payer Considerations -->
        <div class="comparison-section">
            <div class="section-header">
                <h3 class="section-title">
                    <div class="title-icon">
                        <svg viewBox="0 0 24 24" fill="none">
                            <path d="M12 2V22M17 5H9.5C8.57174 5 7.6815 5.36875 7.02513 6.02513C6.36875 6.6815 6 7.57174 6 8.5C6 9.42826 6.36875 10.3185 7.02513 10.9749C7.6815 11.6313 8.57174 12 9.5 12H14.5C15.4283 12 16.3185 12.3687 16.9749 13.0251C17.6313 13.6815 18 14.5717 18 15.5C18 16.4283 17.6313 17.3185 16.9749 17.9749C16.3185 18.6313 15.4283 19 14.5 19H6" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"/>
                        </svg>
                    </div>
                    Market Access & Payer Considerations
                </h3>
            </div>
            
            <div class="info-box">
                <p><strong>Typical Step Therapy Sequence:</strong></p>
                <p>1. Maximally tolerated statin (generic, ~$5-10/month)<br>
                2. Add ezetimibe (generic, ~$10-20/month)<br>
                3. Consider bempedoic acid (if statin intolerant, ~$400/month)<br>
                4. PCSK9 inhibitor consideration (if LDL still >70-100 mg/dL)<br>
                5. Choice between: Inclisiran (2x/year), mAbs (monthly/biweekly), or oral PCSK9i (when available)</p>
            </div>
        </div>

        <!-- Safety Profiles -->
        <div class="comparison-section">
            <div class="section-header">
                <h3 class="section-title">
                    <div class="title-icon">
                        <svg viewBox="0 0 24 24" fill="none">
                            <path d="M12 22C17.5228 22 22 17.5228 22 12C22 6.47715 17.5228 2 12 2C6.47715 2 2 6.47715 2 12C2 17.5228 6.47715 22 12 22Z" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"/>
                            <path d="M12 8V12M12 16H12.01" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"/>
                        </svg>
                    </div>
                    Safety Profiles
                </h3>
            </div>
            
            <div class="table-wrapper">
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Therapy</th>
                            <th>Common AEs</th>
                            <th>Unique Risks</th>
                            <th>Long-term Data</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr class="highlight-row">
                            <td><strong>Inclisiran</strong></td>
                            <td>ISR ~5%</td>
                            <td>None identified</td>
                            <td>4+ years</td>
                        </tr>
                        <tr>
                            <td>PCSK9 mAbs</td>
                            <td>ISR 2-4%, nasopharyngitis</td>
                            <td>None (8+ year record)</td>
                            <td>Excellent</td>
                        </tr>
                        <tr>
                            <td>Bempedoic Acid</td>
                            <td>Well-tolerated</td>
                            <td>Gout 3.5%, tendon rupture 0.5%</td>
                            <td>5+ years</td>
                        </tr>
                        <tr>
                            <td>Statins</td>
                            <td>Muscle pain 5-10%</td>
                            <td>Rare rhabdo, slight diabetes risk</td>
                            <td>30+ years</td>
                        </tr>
                        <tr>
                            <td>Oral PCSK9i</td>
                            <td>Similar to placebo</td>
                            <td>TBD (limited data)</td>
                            <td>Limited</td>
                        </tr>
                        <tr>
                            <td>Gene Editing</td>
                            <td>Under evaluation</td>
                            <td>Off-target edits (theoretical)</td>
                            <td>None</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <!-- 5-10 Year Market Evolution -->
        <div class="comparison-section">
            <div class="section-header">
                <h3 class="section-title">
                    <div class="title-icon">
                        <svg viewBox="0 0 24 24" fill="none">
                            <path d="M12 5V19M5 12H19" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"/>
                        </svg>
                    </div>
                    5-10 Year Market Evolution
                </h3>
            </div>
            
            <div class="timeline">
                <div class="timeline-line"></div>
                
                <div class="timeline-item">
                    <div class="timeline-dot"></div>
                    <div class="timeline-content">
                        <div class="timeline-date">2025-2027</div>
                        <div class="timeline-title">Oral Revolution</div>
                        <div class="timeline-description">
                            â€¢ MK-0616, AZD0780 enter market<br>
                            â€¢ LIB003 approved as monthly option<br>
                            â€¢ Inclisiran ORION-4 validates CV benefit<br>
                            â€¢ Price competition intensifies
                        </div>
                    </div>
                </div>
                
                <div class="timeline-item">
                    <div class="timeline-dot"></div>
                    <div class="timeline-content">
                        <div class="timeline-date">2028-2030</div>
                        <div class="timeline-title">Biosimilar Era</div>
                        <div class="timeline-description">
                            â€¢ PCSK9 mAb biosimilars arrive<br>
                            â€¢ Oral PCSK9i dominate new prescriptions<br>
                            â€¢ Gene editing potentially approved for FH<br>
                            â€¢ Combination pills emerge
                        </div>
                    </div>
                </div>
                
                <div class="timeline-item">
                    <div class="timeline-dot"></div>
                    <div class="timeline-content">
                        <div class="timeline-date">2030-2035</div>
                        <div class="timeline-title">Precision Medicine</div>
                        <div class="timeline-description">
                            â€¢ Personalized therapy selection<br>
                            â€¢ Gene editing for broader populations<br>
                            â€¢ Ultra-low cost generics<br>
                            â€¢ Primary prevention expansion
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>




    
    </body>

    <script>
         function toggleTheme() {
            const body = document.body;
            const sunIcon = document.querySelector('.sun-icon');
            const moonIcon = document.querySelector('.moon-icon');
            
            if (body.classList.contains('light-mode')) {
                body.classList.remove('light-mode');
                body.classList.add('dark-mode');
                sunIcon.style.display = 'none';
                moonIcon.style.display = 'block';
            } else {
                body.classList.remove('dark-mode');
                body.classList.add('light-mode');
                sunIcon.style.display = 'block';
                moonIcon.style.display = 'none';
            }
             sbody = document.getElementById('body');
             sthemeToggle = document.getElementById('themeToggle');
             ssunIcon = document.getElementById('sunIcon');
             smoonIcon = document.getElementById('moonIcon');
            
            if (sbody.classList.contains('dark')) {
                sbody.classList.remove('dark');
                sbody.classList.remove('from-gray-900', 'via-gray-800', 'to-gray-900');
                sbody.classList.add('from-gray-50', 'via-white', 'to-gray-50');
                sthemeToggle.style.transform = 'translateX(0)';
                ssunIcon.style.opacity = '1';
                smoonIcon.style.opacity = '0';
            } else {
                sbody.classList.add('dark');
                sbody.classList.remove('from-gray-50', 'via-white', 'to-gray-50');
                sbody.classList.add('from-gray-900', 'via-gray-800', 'to-gray-900');
                sthemeToggle.style.transform = 'translateX(32px)';
                ssunIcon.style.opacity = '0';
                smoonIcon.style.opacity = '1';
            }
        }

        function filterTrials(filter, event) {
            // Update active button
            const buttons = document.querySelectorAll('.filter-btn');
            buttons.forEach(btn => btn.classList.remove('active'));
            event.target.classList.add('active');

            // Filter rows
            const rows = document.querySelectorAll('#trials-table tbody tr');
            rows.forEach(row => {
                const status = row.getAttribute('data-status');
                if (filter === 'all') {
                    row.style.display = '';
                } else if (filter === status) {
                    row.style.display = '';
                } else {
                    row.style.display = 'none';
                }
            });
        }

        // Check user's preferred color scheme
        if (window.matchMedia && window.matchMedia('(prefers-color-scheme: dark)').matches) {
            toggleTheme();
        }

        // Listen for system theme changes
        window.matchMedia('(prefers-color-scheme: dark)').addEventListener('change', e => {
            if (e.matches && document.body.classList.contains('light-mode')) {
                toggleTheme();
            } else if (!e.matches && document.body.classList.contains('dark-mode')) {
                toggleTheme();
            }
        });

        // Add hover effect to clickable rows
        document.querySelectorAll('.clickable-row').forEach(row => {
            row.style.cursor = 'pointer';
        });
function showTab(tabName) {
    // Hide all tabs
    const tabs = document.querySelectorAll('.tab-content');
    tabs.forEach(tab => tab.classList.remove('active'));
    
    // Remove active from all nav tabs
    const navTabs = document.querySelectorAll('.nav-tab');
    navTabs.forEach(tab => tab.classList.remove('active'));
    
    // Show selected tab
    document.getElementById(tabName).classList.add('active');
    
    // Mark nav tab as active - Find the button that matches this tab
    const activeButton = document.querySelector(`.nav-tab[onclick*="${tabName}"]`);
    if (activeButton) {
        activeButton.classList.add('active');
    }
}
        
        // Animate efficacy bars on load
        window.addEventListener('load', () => {
            const observer = new IntersectionObserver((entries) => {
                entries.forEach(entry => {
                    if (entry.isIntersecting) {
                        const bar = entry.target;
                        const width = bar.style.width;
                        bar.style.width = '0';
                        setTimeout(() => {
                            bar.style.width = width;
                        }, 100);
                        observer.unobserve(bar);
                    }
                });
            });
            
            document.querySelectorAll('.efficacy-fill').forEach(bar => {
                observer.observe(bar);
            });
        });


           function filterTable(filter, event) {
            // Update active button
            const buttons = document.querySelectorAll('.filter-btn');
            buttons.forEach(btn => btn.classList.remove('active'));
            event.target.classList.add('active');

            // Filter rows
            const rows = document.querySelectorAll('tbody tr');
            rows.forEach((row, index) => {
                // Reset animation
                row.style.animation = 'none';
                
                setTimeout(() => {
                    if (filter === 'all') {
                        row.style.display = '';
                    } else if (filter === 'approved' && row.classList.contains('approved')) {
                        row.style.display = '';
                    } else if (filter === 'pipeline' && row.classList.contains('pipeline')) {
                        row.style.display = '';
                    } else if (filter === 'pcsk9' && row.classList.contains('pcsk9')) {
                        row.style.display = '';
                    } else if (filter === 'other' && row.classList.contains('other')) {
                        row.style.display = '';
                    } else {
                        row.style.display = 'none';
                    }
                    
                    // Reapply animation to visible rows
                    if (row.style.display !== 'none') {
                        row.style.animation = `fadeInRow 0.3s ease forwards`;
                        row.style.animationDelay = `${index * 0.05}s`;
                    }
                }, 10);
            });

            // Update stats
            updateStats(filter);
        }

        function updateStats(filter) {
            const rows = document.querySelectorAll('tbody tr');
            let visibleCount = 0;
            let approvedCount = 0;
            let pipelineCount = 0;

            rows.forEach(row => {
                if (filter === 'all' || 
                    (filter === 'approved' && row.classList.contains('approved')) ||
                    (filter === 'pipeline' && row.classList.contains('pipeline')) ||
                    (filter === 'pcsk9' && row.classList.contains('pcsk9')) ||
                    (filter === 'other' && row.classList.contains('other'))) {
                    visibleCount++;
                    if (row.classList.contains('approved')) approvedCount++;
                    if (row.classList.contains('pipeline')) pipelineCount++;
                }
            });

            // Animate stat updates
            const statValues = document.querySelectorAll('.stat-value');
            if (filter !== 'all') {
                statValues[0].textContent = visibleCount;
                statValues[0].style.animation = 'pulse 0.5s ease';
            }
        }

        // Add pulse animation
        const style = document.createElement('style');
        style.textContent = `
            @keyframes pulse {
                0%, 100% { transform: scale(1); }
                50% { transform: scale(1.1); }
            }
        `;
        document.head.appendChild(style);

        // Check user's preferred color scheme
        if (window.matchMedia && window.matchMedia('(prefers-color-scheme: dark)').matches) {
            toggleTheme();
        }

        // Listen for system theme changes
        window.matchMedia('(prefers-color-scheme: dark)').addEventListener('change', e => {
            if (e.matches && document.body.classList.contains('light-mode')) {
                toggleTheme();
            } else if (!e.matches && document.body.classList.contains('dark-mode')) {
                toggleTheme();
            }
        });
    </script>
    
</body>
</html>